New hope for Hard-to-Treat cancers: Next-Gen RET inhibitor enters human trials

NCT ID NCT05443126

Recruiting now Disease control Sponsor: Ellipses Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests a new drug called EP0031 in people with advanced cancers that have a specific genetic change (RET alteration), including non-small cell lung cancer. The trial has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. About 265 adults will take part across multiple sites.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EP0031 (a next-generation RET inhibitor drug)
What this could lead to: If successful, EP0031 could offer a new treatment option for people with advanced RET-altered cancers, especially those who have stopped responding to existing RET inhibitors.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma RET fusion positive cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR NSCLC

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Assistance Publique - Hôpitaux de Marseille
RECRUITING

Marseille, France
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
RECRUITING

Torino, Italy
Centre François Baclesse
RECRUITING

Caen, France
Centre Léon Bérard
RECRUITING

Lyon, France
Centro di Riferimento Oncologico IRCCS
RECRUITING

Aviano, Italy
Charité Comprehensive Cancer Center
RECRUITING

Berlin, Germany
Cleveland Clinic Abu Dhabi (CCAD)
RECRUITING

Abu Dhabi, 112412, United Arab Emirates
David Geffen School of Medicine at UCLA
RECRUITING

Los Angeles, California, 90095, United States
Florida Cancer Specialist
TERMINATED

Fort Myers, Florida, 33908, United States
Florida Cancer Specialists & Research Institute
RECRUITING

West Palm Beach, Florida, 33401, United States
Fondazione IRCCS Istituto Nazionale dei Tumori
NOT_YET_RECRUITING

Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING

Roma, Italy
Georgetown University
RECRUITING

Washington D.C., District of Columbia, 20057, United States
Guy's and St Thomas' Hospital NHSFT
RECRUITING

London, SE1 9RT, United Kingdom
Hospital Madrid Sanchinarro
RECRUITING

Madrid, 28050, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Insular de Gran Canaria
RECRUITING

Las Palmas de Gran Canaria, Spain
Hospital Universitario Ramon y Cajal
RECRUITING

Madrid, 28034, Spain
Hospital Universitario Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
Hospital Universitario de A Coruña
RECRUITING

A Coruña, Spain
Hospital Virgen de la Victoria de Malaga
RECRUITING

Málaga, 29010, Spain
IRCCSS AOU Bologna
RECRUITING

Bologna, Italy
Institut Bergonié
RECRUITING

Bordeaux, France
Institut Gustave Roussy
RECRUITING

Paris, France
Istituto Nazionale Tumori Regina Elena
RECRUITING

Roma, Italy
Karmanos
TERMINATED

Detroit, Michigan, 48201, United States
Ludwig-Maximilians-Universität München (LMU)
NOT_YET_RECRUITING

München, Germany
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 07920, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie
NOT_YET_RECRUITING

Warsaw, Poland
Northwestern University
RECRUITING

Evanston, Illinois, 60208, United States
Providence Portland Medical Centre
RECRUITING

Portland, Oregon, 97213, United States
RUSH University Medical Center
TERMINATED

Chicago, Illinois, 60612, United States
Sarah Cannon Research Institute
TERMINATED

Nashville, Tennessee, 37203, United States
Sheffield Teaching Hospitals NHSFT
WITHDRAWN

Sheffield, S10 2JF, United Kingdom
Sheik Shakhbout Medical City (SSMC)
RECRUITING

Abu Dhabi, 11001, United Arab Emirates
Stanford University
RECRUITING

Stanford, California, 94305, United States
Tawam Hospital
RECRUITING

Al Ain City, Abu Dhabi Emirate, United Arab Emirates
The Christie Hospital NHSFT
RECRUITING

Manchester, M20 4BX, United Kingdom
The Ohio State University - Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
The Royal Marsden NHSFT
RECRUITING

London, SW36JJ, United Kingdom
Thomas Jefferson University
WITHDRAWN

Philadelphia, Pennsylvania, 19107, United States
University College London Hospital (UCLH)
RECRUITING

London, NW1 2BU, United Kingdom
University of Kentucky
TERMINATED

Lexington, Kentucky, 40506, United States
University of Miami - Sylvester Comprehensive Cancer Center
RECRUITING

Miami, Florida, 33136, United States
University of Washington - Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Universitätsklinikum Köln
RECRUITING

Cologne, Germany
Uniwersyteckie Centrum Kliniczne
RECRUITING

Gdansk, Poland
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
Washington University - School of Medicine
RECRUITING

Seattle, Washington, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.